CytoDyn’s CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott A. Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, of CytoDyn will be interviewed on the DrBeen webcast hosted by Mobeen Syed, M.D., M.S. on Tuesday, September 22, 2020 at 6:00 pm PT.

Topics to be covered:

1) CD10: Mild-to-moderate COVID-19 results (U.K., U.S., Philippines, Canada)
2) CD12: Upcoming interim analysis
3) COVID-19: Upcoming trial in “long-haulers”
4) COVID-19: Phase 3 trial in Moderate
5) HIV BLA submission to U.K. and U.S.
6) Leronlimab for stroke victims (blood brain barrier)
7) Upcoming NASH trial and timelines
8) Future of cancer trials with leronlimab

The interview will be available simultaneously on two channels:

YouTube: DrBeen Medical Lectures
Link:  https://www.youtube.com/c/USMLEOnline

Facebook: DrBeen Medical
Link:  https://m.facebook.com/drbeenmedical

Date:   Tuesday, September 22, 2020
Time:   6:00 pm PT

About Coronavirus Disease 2019
CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S.; an interim analysis on the first 195 patients will be announced by mid-October.

About Leronlimab (PRO 140)
The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).